Aoxi Diagnostics Successfully Hosts Its Inaugural Precision Medicine Summit in Shanghai Under the Theme 'Envisioning the Future, Precision in Diagnosis'

VCBeat (WeChat ID: vcbeat) has learned that the inaugural WuXi Diagnostics Precision Medicine Summit, hosted by WuXi Diagnostics and co-organized by International Laboratory Medicine Media, concluded successfully in Shanghai on October 14, 2018. More than 200 leading domestic and international experts in clinical medicine, pathology, and laboratory medicine attended the conference, including Dr. William Morice II, President of Mayo Medical Laboratories and Chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. Participants engaged in in-depth discussions on the latest academic advances in precision diagnosis and treatment, as well as policies and regulations governing in vitro diagnostics.

In recent years, chronic diseases such as malignant tumors and cardiovascular and cerebrovascular disorders have become one of the leading causes of death among urban populations in China. Precision medicine and in vitro diagnostics (IVD) hold broad application prospects for addressing these medical challenges. Therefore, themed “Visioning the Future, Precision Testing,” this summit aims to provide an empowering platform for multi-party participation, mutual exchange, and collaborative innovation in frontier technological advancements in precision medicine in China. Attending experts analyzed the opportunities and challenges facing the precision medicine industry, provided in-depth interpretations of emerging trends, technologies, and applications in in vitro diagnostics, and jointly facilitated the implementation and development of precision medicine in China, thereby benefiting a vast number of patients.

In his opening remarks, Dr. Li Ge, Chairman of WuXi AppTec, stated, “Early this year, WuXi AppTec joined forces with the Mayo Clinic, a world-leading hospital, to establish WuXi Diagnostics through a joint venture, bringing world-class clinical diagnostic capabilities and services to China. We aim to continuously extend the technical expertise and knowledge accumulated by WuXi AppTec over the years into the field of precision medicine. By creating WuXi Diagnostics’ in vitro and clinical diagnostic enablement platform, we empower physicians to deliver better care and ensure patients receive superior treatment.”

Dr. William Morice II, President of Mayo Clinic Laboratories and Chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, stated, “The rapid development of WuXi Diagnostics over just a few months has given us a profound appreciation of the remarkable ‘WuXi Speed,’ and we are fully confident in its future. Mayo Clinic will continue to provide strong support to WuXi Diagnostics, deepen collaborative R&D and industrial partnerships, and accelerate the translation of basic medical research into clinical applications, thereby benefiting patients in China and around the world.”

Dr. Fujun Liu, General Manager of WuXi Diagnostics (right), and Dr. William Morice II, President of Mayo Clinic Laboratories and Chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic (left), pose for a photo at the conference.

Currently, WuXi NextCODE Diagnostics has established a multi-omics clinical diagnostic platform based on cutting-edge testing technologies, covering molecular genetics, proteomics, immunology, metabolomics, pathology, and microbiology. At its Shanghai headquarters and the Mayo Clinic R&D base in Minnesota, USA, the WuXi NextCODE Diagnostics team is simultaneously introducing hundreds of specialized Mayo Clinic tests, with the full introduction of 3,000 such tests expected to be completed by 2019. In the near future, WuXi NextCODE Diagnostics will establish five regional operational centers in East China, North China, South China, Central China, and West China. Based on a two-hour high-speed rail economic circle, it aims to provide high-quality specialized testing services to over 800 million people across China.

“Upholding the grand vision of ‘making no disease difficult to diagnose,’ WuXi Apptec Diagnostics focuses on high-end, precision specialty testing, enhancing physicians’ diagnostic capabilities through a comprehensive, high-standard clinical laboratory platform,” said Dr. Liu Fujun, General Manager of WuXi Apptec Diagnostics. “Looking ahead, WuXi Apptec Diagnostics will dedicate itself to building dual platforms for in vitro diagnostic services and industry empowerment, closely aligning with clinical needs, accelerating the development of innovative specialty tests, integrating multidimensional data, unlocking medical insights, leading precision diagnosis and treatment, and ultimately benefiting human health.”

WuXi Diagnostics, established in early 2018, is a joint venture between WuXi AppTec and Mayo Clinic. Dedicated to building dual platforms for in vitro diagnostic services and industry empowerment, WuXi Diagnostics integrates multidimensional data to unlock medical insights, pioneer precision medicine, and benefit human health, thereby realizing its vision of “making no disease difficult to diagnose.”

WuXi AppTec Group is an internationally leading open-access capabilities and technology platform, providing comprehensive, integrated laboratory research and development (R&D) and manufacturing services—from drug discovery and development to commercialization—for the global pharmaceutical, biotechnology, and medical device industries. The Group’s subsidiaries include: WuXi AppTec (603259.SH), an integrated small-molecule drug R&D and production platform; WuXi Biologics (02269.HK), an integrated biologics manufacturing capabilities and technology platform; WuXi NextCODE, a gene R&D and application service platform; WuXi Diagnostics, an integrated platform for clinical diagnostic product services and data; and YiMing KangDe, among others, which focus on the B2C big health industry sector.

Guided by its core mission of prioritizing research and maintaining a customer-centric approach, WuXi AppTec Group leverages its cost-effective and highly efficient service platforms to help global clients shorten the R&D cycles for drugs and medical devices while reducing R&D costs. The Group’s integrated platforms—covering small molecule drug R&D and manufacturing, biologics R&D and manufacturing, cell and gene therapy R&D and manufacturing, drug R&D and medical device testing, genomics and molecular testing, as well as clinical laboratory and in vitro diagnostics—are currently supporting thousands of innovative R&D projects from more than 3,000 partners across over 30 countries. Committed to delivering the latest and highest-quality pharmaceutical and healthcare products to patients worldwide, WuXi AppTec strives to realize its vision: “To make it easy to develop any drug and cure any disease.”

Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, aiming to provide specialized, integrated care for people around the world who need treatment. For more information, visit mayoclinic.org/about-mayo-clinic or newsnetwork.mayoclinic.org.

The diagnostic divisions of Mayo Clinic’s Department of Laboratory Medicine and Pathology, along with its affiliated Mayo Medical Laboratories, provide premier laboratory and pathology services to more than 4,000 healthcare institutions worldwide. As a globally leading nonprofit organization in healthcare, research, and education, Mayo Clinic channels the revenue generated from these testing services into its investments in medical education and research. Collaborations with diagnostic and biotechnology companies have enabled its test research and development initiatives to grow steadily, with over 100 new tests introduced annually.